Navigation Links
Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
Date:7/28/2011

expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual o
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
2. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
3. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
4. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
5. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
6. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
7. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
8. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
9. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
10. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
11. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)...  Alere Inc. (NYSE: ALR ), a ... Juliet Cunningham as Vice President, Investor Relations. In ... driving communications with the investment community. "As ... to increase shareholder value, it is critical that we ... Chief Executive Officer. "We are delighted that Juliet ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/22/2014)... Nov. 22, 2014 (HealthDay News) -- The wide variety ... pose a threat for people with food allergies, an ... are so many types of food allergies that it ... the holidays," Dr. Guha Krishnaswamy, director of allergy and ... in a hospital news release. "If you know ...
(Date:11/22/2014)... Recently, UWDress.com is gratified to introduce its new ... addition, the company has also offered an attracting discount ... online supplier of wedding dresses, UWDress.com is good at ... wedding guest gowns are provided over 20 colors, which ... selection is famous for high quality. Therefore, its sales ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Developers and plugin ... new plugin entitled FCPX 3D Model bringing the impossible to ... Model allows users to add obj files to FCPX enabling ... Studios. “Blurring the line between professional and armature, FCPX 3D ... Pixel Film Studios allows Final Cut Pro X users to ...
(Date:11/22/2014)... (HealthDay News) -- Many young people consider hookahs a ... study finds fumes from the water pipes contain the ... increased risk for leukemia in prior research, according to ... Cancer Epidemiology, Biomarkers & Prevention . "In ... not a safe alternative to smoking other forms of ...
(Date:11/21/2014)... CT (PRWEB) November 21, 2014 CRN ... a veteran radio industry sales professional to its award-winning ... brings 30 years of leadership and sales experience to ... and assume the title of Director of Strategy and ... Development, Robert O’Mara. , Heinemann will handle a wide ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Pixel Film Studios released FCPX 3D Model plugin Exclusively for Final Cut Pro X 2Health News:Hookahs Deliver Toxic Benzene in Every Puff, Study Shows 2Health News:Radio Industry Veteran Joins CRN International’s Sales Organization in Detroit 2
... WASHINGTON, Oct. 1 Today the Senate ... secured by,Senator John Kerry (D-Mass.) to extend the ... to increase the transition and,commercialization of products developed ... the thousands of firms that participate in the,program ...
... Board Chair, Named Executive ... Chairman, ... ), a biopharmaceutical company focused on the discovery,and development of drugs for ... that Corey Goodman,Ph.D., will step down today as President and Chief Executive ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... from Positive VENT Trial Presented at ERS 17th ... 1 Emphasys Medical Inc.,today announced the submission ... Food and Drug Administration (FDA) requesting regulatory,approval to ... in,the United States. The Zephyr EBV is a ...
... period of time after leaving the foster care system ... those with stable housing situations, according to a report ... Adolescent Medicine, one of the JAMA/Archives journals. Youth who ... leaving the foster care system appear to have more ...
... Behavioral,Health System, a UHS facility, has announced the ... teens in crisis. The new treatment,center is associated ... http://www.highlandsbhs.com ) in Littleton, Colo. Highlands Behavioral ... of Excellence represents an expansion of the Adolescent,Unit ...
Cached Medicine News:Health News:Kerry Extends, Improves Small Business Innovation Program 2Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Medicine Products: